Jardiance (Empagliflozin), an SGLT2 Inhibitor, Receives FDA Approval for the Treatment of Patients with Type 2 Diabetes
about
Jardiance (Empagliflozin), an SGLT2 Inhibitor, Receives FDA Approval for the Treatment of Patients with Type 2 Diabetes
description
2015 nî lūn-bûn
@nan
2015年の論文
@ja
2015年学术文章
@wuu
2015年学术文章
@zh-cn
2015年学术文章
@zh-hans
2015年学术文章
@zh-my
2015年学术文章
@zh-sg
2015年學術文章
@yue
2015年學術文章
@zh
2015年學術文章
@zh-hant
name
Jardiance (Empagliflozin), an ...... Patients with Type 2 Diabetes
@ast
Jardiance (Empagliflozin), an ...... Patients with Type 2 Diabetes
@en
type
label
Jardiance (Empagliflozin), an ...... Patients with Type 2 Diabetes
@ast
Jardiance (Empagliflozin), an ...... Patients with Type 2 Diabetes
@en
prefLabel
Jardiance (Empagliflozin), an ...... Patients with Type 2 Diabetes
@ast
Jardiance (Empagliflozin), an ...... Patients with Type 2 Diabetes
@en
P2860
P1476
Jardiance (Empagliflozin), an ...... Patients with Type 2 Diabetes
@en
P2093
Loretta Fala
P2860
P433
Spec Feature
P577
2015-03-01T00:00:00Z